Economidou-Karaoglou A, Lans M, Taper H S, Michaux J L, Roberfroid M
Unité de Biochimie Toxicologique et Cancérologique et, Faculté de Médecine, Université de Louvain, Bruxelles, Belgique.
Cancer. 1988 May 1;61(9):1838-43. doi: 10.1002/1097-0142(19880501)61:9<1838::aid-cncr2820610920>3.0.co;2-r.
Our previously published clinical results suggest that the variations in serum alkaline DNase activity (SADA) could be a reliable marker for the therapeutic monitoring of different human malignancies. The aim of the study documented in this was to determine SADA variations in 27 patients suffering from malignant lymphomas (Hodgkin's and non-Hodgkin's). Patients continued to be observed after therapy. The blood samples were collected before treatment (Time 0), during several days from the onset of each treatment (Phase I), and weeks after the last therapy (Phase II). A decrease in the serum alkaline DNase activity during the first treatment indicates a good clinical response; no decrease indicates a nonresponse to treatment (Phase I). The Phase II data can be used to predict the long-term evolution of the disease. In patients who respond to therapy three types of variations of SADA are observed during this phase. A progressive regain of SADA up to a value exceeding the level of initial value (T0) correlates with a complete remission. An incomplete regain of activity corresponds to a partial remission. No regain of SADA precedes death.
我们之前发表的临床结果表明，血清碱性脱氧核糖核酸酶活性（SADA）的变化可能是不同人类恶性肿瘤治疗监测的可靠标志物。本文记录的研究目的是确定27例恶性淋巴瘤（霍奇金淋巴瘤和非霍奇金淋巴瘤）患者的SADA变化。治疗后持续观察患者。在治疗前（时间0）、每次治疗开始后的几天内（I期）以及最后一次治疗后的几周（II期）采集血样。首次治疗期间血清碱性脱氧核糖核酸酶活性降低表明临床反应良好；无降低表明对治疗无反应（I期）。II期数据可用于预测疾病的长期演变。在对治疗有反应的患者中，在此阶段观察到SADA的三种变化类型。SADA逐渐恢复到超过初始值（T0）水平的值与完全缓解相关。活性不完全恢复对应部分缓解。SADA未恢复先于死亡。
